**Clostridium difficile Infection**

**Summary**

*Clostridium difficile* (or *C. diff*) is a spore-forming bacterium that can result in asymptomatic colonization or clinical infection. *Clostridium difficile* infection (CDI) causes diarrhea that can range from mild to severe and can even be life-threatening. Signs and symptoms can include watery diarrhea, fever, abdominal pain/tenderness, nausea, and loss of appetite. Serious sequelae, such as pseudomembranous colitis, toxic megacolon, perforations of the colon, sepsis, and death may result from CDI. It is also possible for a person to be colonized with *C. difficile*, and thus not exhibit any clinical signs or symptoms; studies have shown approximately 5% of the general population, and 50% or more of other populations, such as hospitalized patients, residents of long-term care facilities and infants under one year of age, are colonized with *C. difficile*. After treatment for CDI, repeat testing (“test of cure”) is not recommended if signs and symptoms have resolved, as some persons may remain colonized for an undetermined period of time, perhaps weeks to months.

Risk for CDI is increased in persons with recent or prolonged antibiotic exposure, long length of stay in healthcare settings, gastrointestinal surgery and/or manipulation, serious underlying chronic health conditions, immunocompromised status, advanced age, and proton pump inhibitor use. Although CDI remains primarily associated with healthcare exposure, recently infections have been more commonly reported in traditionally ‘low risk’ individuals, such as healthy persons in the community and peripartum women. Changes to the prevalence of CDI may be in part due to the emergence of a more virulent strain of *C. difficile*, known as the restriction enzyme analysis type BI, North American Pulsed Field type 1 (NAP1), or PCR ribotype 027 (BI/NAP1/027). Judicious use of antibiotics, proper contact precautions, and environmental cleaning and disinfection are important prevention strategies for CDI.

**Agent**

*Clostridium difficile* is a Gram-positive, spore-forming, anaerobic bacillus that produces two exotoxins: toxin A and toxin B. The epidemic BI/NAP1/027 strain appears to be more virulent due to increased production of toxins A & B, production of a third toxin called binary toxin, as well as other factors currently being studied. In addition, BI/NAP1/027 is resistant to fluoroquinolones.

**Transmission**

**Reservoir:**

Humans are the most important reservoir, though it is also found in many domestic and food animal species. Can be isolated from soil; however, any surface, device, or material (e.g., electronic rectal thermometers, commodes, bathing tubs, remote controls) that becomes contaminated with feces may serve as a reservoir for *C. difficile* spores.

**Mode of transmission:**

*C. difficile* is spread through the fecal-oral route. *C. difficile* spores may also be transferred to patients via the hands of healthcare personnel who have touched a contaminated item or surface.

**Period of communicability:**

Person-to-person spread occurs from both symptomatic patients and asymptomatic carriers. *C. difficile* spores are highly resistant to desiccation, killing by alcohol and standard EPA-
registered hospital disinfectants, and can survive in the environment (such as on surfaces or contaminated items) for months or years.

**Clinical Disease**

**Incubation period:**

The incubation period of CDI following medical interventions or organism acquisition has not been clearly defined. Although one study suggested a short incubation period of less than 7 days, others supported a time frame of up to 3 months after completion of antibiotic therapy. Thus, many cases of healthcare-associated CDI may have their onset in the community after hospitalization or medical care.

**Illness:**

Symptomatic *Clostridium difficile* infection causes inflammation of the colon, or colitis. Symptoms may include mild-to-severe watery diarrhea, fever, abdominal pain/tenderness, nausea, and loss of appetite. In severe cases, pseudomembranous colitis, toxic megacolon, perforations of the colon, sepsis, and/or death may occur. However, many studies show that over half of hospital patients and up to 80% of infants under one year of age are asymptotically colonized. *C. difficile* accounts for 20–30% of antibiotic-associated diarrhea.

**Laboratory Diagnosis**

Most diagnostic testing for *C. difficile* is based on detection of toxin B and/or toxin A in a diarrheal stool specimen or detection of the genes encoding for toxin production. Testing should be performed only on unformed stool unless ileus (i.e., blockage of the intestines caused by a lack of peristalsis) is suspected. Testing for cure and testing on asymptomatic patients is not clinically useful and thus not recommended except for epidemiological studies. Enzyme immunoassay (EIA) tests, which detect toxins A and B, offer rapid turn-around time but have a relatively low sensitivity. A two-step algorithm testing approach, using the more sensitive but nonspecific EIA test for glutamate dehydrogenase (GDH) combined with toxin testing, is often used. A more sensitive and specific approach which has become more widely available is molecular assay testing using nucleic acid amplification tests (NAATs) (e.g., PCR). NAAT may be used as a stand-alone test or as confirmatory testing for discrepant toxin/GDH tests. Stool culture for *C. difficile*, though the most sensitive test available, is labor intensive and has a relatively slow turn-around time and is therefore less clinically useful. *Clostridium difficile* toxin degrades at room temperature and can be undetectable within 2 hours of stool specimen collection. Specimens should be promptly tested and kept refrigerated at 4°C to minimize the occurrence of false-negative results.

**Treatment**

Discontinuation of the potentially precipitating antimicrobial therapy should occur as soon as possible. In approximately 20% of patients, symptomatic CDI will resolve within 2–3 days of discontinuation of antibiotic exposure. Infection can usually be treated with a 10-day course of oral metronidazole, vancomycin, or recently approved fidaxomicin. Metronidazole is usually the drug of choice for initial treatment of mild to moderate cases; oral vancomycin or vancomycin administered via enema plus intravenous metronidazole is indicated for patients with severe disease or for patients who do not respond to metronidazole. Intravenous vancomycin is not effective for *C. difficile* infection.

Relapse occurs in up to 25% of all cases. Tapered or pulse doses of vancomycin are often used for relapsed cases. Metronidazole should not be used for chronic therapy, because of risk for
neurotoxicity. Investigational therapies include fecal transplantation, probiotics, immune globulin therapy, toxin binders, and other antimicrobial agents (tinidazole, nitazoxanide, rifaximin).

**Surveillance**

**Case definition:**

The Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE) have not developed case definitions for CDI. The New Mexico Department of Health currently conducts two types of CDI surveillance: 1) statewide CDI laboratory surveillance through hospitals that identify cases through positive *C. difficile* toxin assays or positive *C. difficile* molecular assays (e.g., PCR) on stool specimens following National Health Safety Network (NHSN) LabID event protocols; and 2) population-based surveillance in Bernalillo County only through the New Mexico Department of Health Emerging Infections Program (NM EIP) following national EIP surveillance protocols.

**Reporting:**

Report all suspected or confirmed cases of CDI to the Epidemiology and Response Division (ERD). Information needed includes: patient's name, age, date of birth, sex, race, ethnicity, home address, home phone number, occupation, specimen collection date, and health care provider.

**Control Measures**

1. **Case management**
   
   a. Isolation: Standard precautions, contact precautions, and a private room for a hospitalized patient (if feasible) are recommended for the duration of illness. Frequent hand washing, and good personal hygiene should be emphasized. In normal situations, a patient with CDI can be removed from contact isolation when diarrhea resolves; however, some organizations recommend continuing Contact Precautions for at least 48 hours after diarrhea resolves. If there is an outbreak or evidence of ongoing *C. difficile* transmission, consider extending contact isolation until the patient is discharged, or extending isolation until the patient is without diarrhea for 2 days. Test of cure is not recommended. Inter-facility communication should occur upon patient discharge or transfer and should include information about the CDI infection status of the patient.
   
   b. Prophylaxis: Not applicable.

2. **Contact management**
   
   a. Isolation: None required.
   
   b. Prophylaxis: Not applicable.

3. **Prevention**
   
   a. Education: Meticulous hand hygiene, proper handling of contaminated surfaces, disinfection of fomites, and judicious use of antibiotics are the best available methods for controlling CDI. Healthcare providers should use gloves when caring for patients with CDI and should wash hands with soap and water after glove removal. Alcohol-based hand hygiene products do not kill *C. difficile* spores. Thorough cleaning of rooms and bathrooms of patients with *C. difficile* is essential. To ensure proper environmental cleaning and disinfection of any shared medical equipment, facilities should consider using an Environmental Protection Agency (EPA)-registered disinfectant with a sporicidal claim for
environmental surface disinfection and/or 10% hypochlorite solution (e.g., household chlorine bleach). Standard EPA-registered hospital disinfectants are not effective against *C. difficile* spores.

b. Immunization: Not applicable

**Management of CDI in Child Care Centers and Long-Term Care Facilities**

Children with *C. difficile* diarrhea should be excluded from child care settings for the duration of the diarrhea.

Long-term care facility residents with suspect or confirmed CDI should be under appropriate contact precautions, using the least restrictive approach possible that offers adequate protection but does not adversely affect psychosocial well-being. Residents with the ability to maintain adequate personal hygiene should be allowed to participate in group activities when possible, after performing hand hygiene, disinfecting assistive devices (walkers, canes, wheelchairs), and gowning before leaving their room. Residents unable to comply with good hygiene may benefit from a 1:1 caregiver. Guidelines for room assignment strategies can be found in the 2013 APIC Guide to Eliminating *Clostridium difficile* Infections. Healthcare workers should use contact precautions when in the resident’s room and maintain meticulous hand hygiene (see 3. Prevention a. Education above). Medical devices and equipment should be dedicated to single resident use or be disinfected between uses; rectal thermometers should not be used. The CDC NHSN offers a free, voluntary, internet-based surveillance system to allow long-term care facilities to enter data and compare infection rates.

Contact the Epidemiology and Response Division at 505-827-0006 for further recommendations.

**References**


Clinical Practice Guidelines for *Clostridium difficile*. Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).
See *Clostridium difficile* Fact Sheets ([English](#)) ([Spanish](#)).